Sagimet Biosciences (SGMT) director sells 18,844 shares under 10b5-1 plan

Rhea-AI Filing Summary

George Kemble, a director of Sagimet Biosciences Inc., sold 18,844 shares of Series A Common Stock on July 20, 2026, at a weighted average price of $7.4575 per share in open-market or private transactions under a Rule 10b5-1 trading plan adopted on August 21, 2025. After these sales, he directly holds 62,161 shares. The reported trades occurred at prices ranging from $7.17 to $7.97 per share.

Insider Trade Summary 10b5-1

Net Seller: 18,844 shares

Net Sell 1 txn

Insider Kemble George

Role Director

Sold 18,844 shs ($141K)

Type	Security	Shares	Price	Value
Sale	Series A Common Stock F1, F2	18,844	$7.4575	$141K

Holdings After Transaction: Series A Common Stock — 62,161 shares (Direct)

Footnotes (2)

1. F1. These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.17 to $7.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 18,844 shares Weighted average sale price: $7.4575 per share Sale price range: $7.17 to $7.97 per share +2 more

5 metrics

Shares sold 18,844 shares Series A Common Stock sold by director George Kemble on July 20, 2026

Weighted average sale price $7.4575 per share Aggregate price for 18,844 shares sold on July 20, 2026

Sale price range $7.17 to $7.97 per share Multiple transactions within this range on July 20, 2026

Shares owned after sale 62,161 shares Direct holdings of George Kemble following the reported sale

Rule 10b5-1 plan adoption date August 21, 2025 Adoption date of trading plan used for these sales

Key Terms

Rule 10b5-1 trading plan, weighted average price, Series A Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"These sales were effected ... pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Series A Common Stock financial

"security title: Series A Common Stock reported for this transaction"

Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/22/2026 - 04:05 PM Accepted by SEC EDGAR 07/22/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What insider transaction did Sagimet Biosciences (SGMT) report for director George Kemble?

Director George Kemble reported selling 18,844 shares of Sagimet Biosciences Series A Common Stock on July 20, 2026. The transaction was executed as open-market or private sales under a pre-established Rule 10b5-1 trading plan adopted on August 21, 2025.

At what prices were the SGMT shares sold in George Kemble’s reported transaction?

The shares were sold at a weighted average price of $7.4575 per share. Individual trades occurred in multiple transactions at prices ranging from $7.17 to $7.97, inclusive, as disclosed in the transaction footnote.

How many Sagimet Biosciences (SGMT) shares does George Kemble hold after this sale?

Following the reported sale, George Kemble directly holds 62,161 shares of Sagimet Biosciences Series A Common Stock. This post-transaction holding reflects his remaining direct ownership position after selling 18,844 shares on July 20, 2026.

Was George Kemble’s SGMT stock sale made under a Rule 10b5-1 trading plan?

Yes, the sales were made under a Rule 10b5-1 trading plan adopted on August 21, 2025. The company also affirms the Rule 10b5-1 status, indicating these trades were pre-arranged rather than discretionary at the time of execution.

What type of security did George Kemble sell in Sagimet Biosciences (SGMT)?

George Kemble sold Series A Common Stock of Sagimet Biosciences Inc., totaling 18,844 shares. The sales were reported as non-derivative transactions, meaning they involved actual common shares rather than options or other derivative securities.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kemble George

(Last) (First) (Middle)

SAGIMET BIOSCIENCES INC.

950 TOWER LANE, SUITE 1500

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sagimet Biosciences Inc. [ SGMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Series A Common Stock	07/20/2026		S(1)		18,844	D	$7.4575(2)	62,161	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.17 to $7.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Elizabeth Rozek, Attorney-in-Fact	07/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)